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peated injury of the airway epithelium caused by hyperpnoea of
poorly conditioned air has been proposed as a key factor in the
pathogenesis of exercise-induced bronchoconstriction (EIB) in ath-
letes. In animals, the short-acting 2-agonist terbutaline has been
shown to reduce dry airflow-induced bronchoconstriction and the
associated shedding of airway epithelial cells. Our aim was to test the
efficacy of inhaled terbutaline in attenuating hyperpnoea-induced
bronchoconstriction and airway epithelial injury in athletes. Twenty-
seven athletes with EIB participated in a randomized, double-blind,
placebo-controlled, crossover study. Athletes completed an 8-min
eucapnic voluntary hyperpnoea (EVH) test with dry air on two
separate days 15 min after inhaling 0.5 mg terbutaline or a matching
placebo. Forced expiratory volume in 1 s (FEV1) and urinary concen-
tration of the club cell (Clara cell) protein 16 (CC16, a marker of
airway epithelial perturbation) were measured before and up to 60 min
after EVH. The maximum fall in FEV1 of 17  8% (SD) on placebo
was reduced to 8 5% following terbutaline (P 0.001). Terbutaline
gave bronchoprotection (i.e., post-EVH FEV1 fall10%) to 22 (81%)
athletes. EVH caused an increase in urinary excretion of CC16 in both
conditions (P  0.001), and terbutaline significantly reduced this rise
(pre- to postchallenge CC16 increase 416  495 pg/mol creatinine
after placebo vs. 315  523 pg/mol creatinine after terbutaline, P 
0.016). These results suggest that the inhalation of a single therapeutic
dose of terbutaline offers significant protection against hyperpnoea-
induced bronchoconstriction and attenuates acute airway epithelial
perturbation in athletes.
exercise-induced bronchoconstriction; epithelial injury; inhaled 2-
agonist; Clara cell
EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB) is defined as a
transient narrowing of the airways that occurs during or shortly
after strenuous exercise. The main stimulus for EIB is evapo-
rative water and heat loss from the airway surface as a
consequence of heating and humidifying large volumes of
unconditioned air (2). Whereas EIB can be found in both the
general population and in athletes, the latter are more at risk for
EIB (11), and they often develop EIB later in life (16). We
have previously proposed that, in athletes, EIB is a conse-
quence of repeated injury and repair of the airway epithelium
in response to long hours of conditioning air during strenuous
training (3).
During exercise, as ventilation increases, the conditioning of
inspired air extends progressively toward the peripheral air-
ways. If the replacement of water to the airway surface is
insufficient, dehydration injury of the distal airways may occur
(3). In addition, mechanical stress associated with high airflow
and/or bronchoconstriction may accelerate disruption of the
epithelial cell layer (24). Following epithelial injury, bulk
plasma may leak from the microcirculation to repair the dam-
age to the epithelial cells (35). The process of plasma exuda-
tion could then expose the airway smooth muscle to substances
that alter its growth and affect its contractile properties, leading
to the development of airway hyperresponsiveness and EIB in
susceptible individuals (3). In support of this idea, increased
levels of bronchial epithelial cells have been found in induced
sputum of asthmatic patients with EIB (18), as well as in
various athletic populations [elite swimmers (8) and recre-
ational runners (12)]. Increases in tenascin expression and
inflammatory cell counts in the lung biopsies of elite cross-
country skiers (23) and of elite swimmers (7) have also
provided direct evidence of exercise-induced airway remodel-
ing (a sign of repeated injury-repair) and inflammation.
Using the concentration of the lung-specific club cell (Clara
cell) protein (CC16) in extrapulmonary fluids, our group pre-
viously established that dry air hyperpnoea causes an acute
perturbation of the airway epithelium (6). Consistent with our
finding, serum and urinary CC16 concentration have also be
shown to increase following bouts of cycling (9), running (12,
29), and swimming (10, 17, 37). In swimming, however,
because of the noxious effect of trichloramines on club cell
function (10), exposure to chlorination by-products may act as
a confounder (27). In our recent study on running (5), we
showed that inhalation of warm humid air attenuated the rise in
urinary CC16 postexercise (likely as a result of a reduced water
loss from the airway surface). We are now aiming to establish
whether pharmacological agents also have the potency to blunt,
or even to completely abolish, the CC16 response associated
with exercise hyperpnoea.
In a healthy human epithelium, airway surface liquid is
mainly regulated via apical Cl secretion and Na absorption
[passive flow of water occurring along the osmotic gradient
(21)]. Pharmacological interventions can modify ion transport.
In vitro, the 2-agonist terbutaline has been shown to increase
the transport of Cl toward the airway lumen (14). Moreover,
in canine peripheral airways challenged with dry air, infusion
of terbutaline attenuated airway narrowing and reduced epithe-
lial cell shedding (40). To date, the impact of pharmacological
agents administered directly to the airways has not been tested.
We reasoned that, if terbutaline facilitates replacement of water
at the airway surface level during exposure to dry air, pretreat-
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ment with inhaled terbutaline may attenuate hyperpnoea-in-
duced airway injury in humans.
In this study, we tested the efficacy of a single dose of
inhaled terbutaline at reducing hyperpnoea-induced airway
epithelial perturbation in athletes. We also aimed to confirm
the bronchoprotective effect of terbutaline in athletes with EIB.
Our hypothesis was that 0.5 mg terbutaline will attenuate the
increase in urinary concentration of CC16 and the fall in forced
expiratory volume in 1 s (FEV1) following 8 min of eucapnic
voluntary hyperpnoea (EVH) with dry air in athletes.
METHODS
Subjects. The study population consisted of 27 athletes with EIB.
EIB was confirmed by a fall of 10% in FEV1 following an 8-min
EVH challenge during a screening visit. Participants were nonsmok-
ers, free from respiratory infections for 4 wk before the study, and
with no known chronic medical condition other than asthma or EIB.
Regular swimmers (1 h/wk) were excluded. Participants abstained
from alcohol, caffeine, and exercise on the day of testing, and
medication was withheld as follows: short-acting 2-agonist (SABA)
treatments were withheld for a minimum of 8 h, long-acting 2-
agonist (LABA) treatments for 24 h, inhaled corticosteroid (ICS)
treatments for 12 h, and combination therapies of LABA ICS for 24
h (28). Written informed consent was obtained from all participants
after the study protocol, and potential risks were explained. The study
was approved by the United Kingdom National Health Service Re-
search Ethics Committee (NHS REC reference no.: 10/H0716/30).
Experimental design. The study used a randomized, double-blind,
placebo-controlled, crossover experimental design. All participants
attended two experimental visits, separated by at least 2 days but no
more than 3 wk, during which they were administered either 0.5 mg
of terbutaline or a placebo 15 min before completion of an EVH
challenge. The primary end points were changes in urinary CC16
concentration and FEV1.
Experimental visits were conducted in the morning between 8:00
and 11:00 A.M. [to standardize for fluctuations in CC16 levels
throughout the day (4)] and started with the recording of baseline lung
function. The active drug (i.e., 0.5 mg of terbutaline) was adminis-
tered via a dry powder inhaler (Bricanyl Turbohaler; Astra Zeneca,
London, UK). An empty demonstration Turbohaler was used for
administration of the placebo. Subjects were instructed to take one
deep, hard inhalation of the drug or placebo and to hold their breath
for 10 s. Posttreatment lung function manoeuvers were repeated at 10
min. The EVH challenge started 15 min after treatment. Spontaneous
recovery of FEV1 to baseline levels following the EVH challenge was
measured at 2, 5, 10, 15, 20, 30, and 60 min.
Subjects ingested 200 ml of water 1 h before each visit. They
ingested a further 400 ml upon arrival at the laboratory and then 200
ml at 30-min intervals. Two baseline urine samples were obtained: the
first, on arrival at the laboratory, which was discarded; the second,
30–60 min later and immediately before administration of the drug,
which was used as baseline. Further urine samples were collected 30
and 60 min after the EVH challenge. All samples were stored, without
preservatives, at80°C. Atopic status was tested by skin prick testing
during the first experimental visit, with the procedure starting 40 min
post-EVH.
CC16 analysis. To avoid prostatic contamination, the first 100 ml
of urine were systematically discarded in male participants (4). CC16
was measured using the Human Clara Cell Protein ELISA kit from
BioVendor (Modrice, Czech Republic) according to the manufactur-
er’s instructions. The detection limit for CC16 was 20 pg/ml. All urine
samples were analyzed for creatinine using a COBAS 6000 analyzer
(Roche Diagnostics, Bromma, Sweden). CC16 results were expressed
as picograms of excreted mediator per micromole of creatinine.
Lung function measurements. Forced expiratory manoeuvers were
conducted using a spirometer (MicroLoop, Micromedical, Kent, UK)
in accordance with ERS/ATS guidelines (28). Manoeuvers were
repeated in triplicate at baseline and in duplicate postchallenge. The
equations of Quanjer et al. (36) were used for calculation of predicted
values. At all pre- and post-EVH time points, the best FEV1 and
forced vital capacity (FVC) values of two reproducible manoeuvers
were kept for analysis. The maximum fall in FEV1 and FVC was
expressed as a percentage from the posttreatment value. The trape-
zoidal method was used to calculate the area under the FEV1 time
curve (FEV1-AUC0–60) and was calculated from the posttreatment
FEV1 value. The degree of bronchoprotection afforded by terbutaline
was calculated by subtracting the maximum fall in FEV1 on the drug
treatment day from the maximum fall in FEV1 on the placebo day, and
expressing it as a percentage of the placebo. The largest peak expi-
ratory flow (PEF) value from the three (baseline) or two (post-EVH)
reproducible manoeuvers was recorded at each time point. Mean
forced expiratory flow between 25 and 75% of the FVC (FEF25–75)
and instantaneous forced expiratory flows at 25, 50, and 75% of FVC
(FEF75, FEF50, and FEF25, respectively) were taken from the manoeu-
vers with the largest sum of FEV1 and FVC.
EVH challenge. An 8-min EVH challenge was performed on a
Eucapsys system (SMTEC, Nyon, Switzerland), with dry gases drawn
from medical gas cylinders. Briefly, participants breathed a gas
mixture containing 5% CO2, 20% O2, and balance N2 at a target
ventilation of 85% predicted maximum voluntary ventilation (MVV),
calculated as 30 times baseline FEV1 (1). The ventilation achieved
during the first visit was used as the target ventilation for the second
visit.
Atopic status. A skin prick test was carried out using standardized
allergen extracts of house dust mite, timothy grass, and cat hair
(ALK-Abello, Reading, UK). Saline and histamine were used as
negative and positive controls, respectively. A test was defined pos-
itive if the reaction wheel was 3 mm.
Data analysis. Sample size requirement was dictated by our pre-
vious work (5). With 21 participants we were previously able to detect
a between-condition effect in urinary CC16 excretion following bron-
chial provocation challenge. All data were checked for normality
using the Shapiro-Wilk test. CC16 data were not normally distributed;
therefore, natural logarithmic transformation was applied. Differences
between conditions for FEV1 (in l) and CC16 were analyzed using
paired-sample t-test. FEV1 maximum fall post-EVH (in %) and
FEV1-AUC0–60 were nonnormally distributed and therefore analyzed
using a Wilcoxon signed-rank test. Differences between conditions
and times were analyzed using a repeated-measures ANOVA. In cases
of statistical significance, least-significance difference pairwise com-
parisons were conducted post hoc. Data were analyzed using SPSS
18.0 for Windows (SPSS, Chicago, IL), and significance was assessed
at the 0.05 level. Results are expressed as means  SD, unless
otherwise stated.
RESULTS
Participant characteristics. Twenty seven participants (11
females) completed the study. Mean age, height, and body
mass were 27  9 yr, 174  8 cm, and 74  13 kg,
respectively. Participants were involved in summer sports
(athletics, cycling, football, rugby, or rowing) and trained for
8  3 h/wk in aerobic activities. Twenty three participants
competed at a local level and three competed at the national or
international level. Participants had 9  6 yr of experience in
their sport. Participants’ medical diagnosis, current treatment,
and atopic status are presented in Table 1. One participant had
an underlying diagnosis of Crohn’s disease. However, at the
time of the study, he was asymptomatic and was not treated for
this condition. During the screening visit, baseline FEV1 was
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80% predicted in all participants, and the fall in FEV1
post-EVH averaged 19  10% (Table 1).
Baseline lung function and ventilation level during EVH.
There was no difference between experimental visits in base-
line lung function parameters (Table 2). Terbutaline had a
small (5  3% increase in FEV1) but statistically significant
bronchodilator effect (P  0.001, Table 2). FEF25–75, FEF25,
FEF50, FEF75, and PEF also significantly increased postadmin-
istration of terbutaline (P  0.001), whereas FVC remained
unchanged (Table 2). No significant change in lung function
was observed following administration of the placebo (Table
2). Minute ventilation was slightly but significantly larger in
the terbutaline condition compared with the placebo condition:
102  20 vs. 101  20 l (P  0.047). Participants reached
Table 1. Participant characteristics
ID No. Gender Atopic Status
Baseline FEV1,
%pred Previous Diagnosis Treatment
Prescribed ICS
Dose, g/day
Post-EVH Maximum FEV1 Fall, %
Protection, %Screening Placebo Terbutaline
1 M  95 Asthma  EIB Combination, SABA 1,600 17 18 15 17
2 M  92 Asthma SABA, ICS 200 50 13 5 62
3 M  99 Asthma  EIB Combination 400 16 12 18 0
4 F  108 EIB SABA, ICS 200 21 13 12 8
5 M  97 16 15 4 73
6 F  92 Asthma SABA, ICS 200 10 14 8 43
7 M  93 Asthma  EIB SABA 23 21 8 63
8 M  102 Asthma SABA 21 12 5 58
9 F  93 Asthma Combination 400 10 13 2 85
10 M  99 Asthma SABA, ICS 600 36 26 25 4
11 M  99 11 11 6 45
12 M  85 Asthma 9 14 6 57
13 F  103 Asthma 27 29 9 69
14 M  109 EIB SABA 14 11 7 36
15 F  99 Asthma  EIB Combination 400 19 16 7 56
16 F  109 12 20 11 45
17 M  94 Asthma SABA 18 17 1 94
18 M  85 Asthma Combination 200 14 13 6 54
19 M  109 Asthma  EIB ICS 100 14 15 9 40
20 F  96 Asthma SABA 12 10 8 20
21 M  94 Asthma SABA 15 13 7 46
22 M  111 Asthma SABA, ICS 200 16 16 1 94
23 F  102 EIB SABA, ICS 200 23 28 6 79
24 F  86 Asthma SABA 28 22 8 64
25 F  88 EIB 10 11 1 91
26 F  82 Asthma  EIB SABA 46 47 6 87
27 M  91 Asthma SABA 16 11 2 81
Mean  SD 97 8 19  10 17  8 8  5*** 54  28
M, male; F, female; Atopic status: , positive skin prick response to house dust mite, timothy grass, and/or cat hair; FEV1 %pred, baseline forced expiratory
volume in 1 s expressed relative to the predicted value (36); EIB, exercise-induced bronchoconstriction; SABA, short-acting 2-agonist; LABA, long-acting
2-agonist; ICS, inhaled corticosteroids; combination, combination therapy of LABA and ICS; post-EVH maximum FEV1 fall, maximal fall in FEV1 after
eucapnic voluntary hyperpnoea; protection, % bronchoprotection afforded by terbutaline. ***Significantly different from placebo (P  0.001).
Table 2. Lung function results
Lung Function Measurement Pre-Rx Post-Rx Post-EVH, min value
Pre-Rx vs. Post-Rx
(P Value)
Post-Rx vs. Post-EVH
(P Value)
Placebo
FEV1, l 3.68  0.65 3.67 0.67 3.06  0.68 0.316 0.001
FVC, l 4.74  0.93 4.76 0.95 4.48  1.04 0.798 0.001
FEF25–75, l/s 3.27  0.90 3.27 0.90 2.17  0.69 0.741 0.001
FEF25, l/s 6.18  1.23 6.12 1.23 4.39  1.30 0.495 0.001
FEF50, l/s 3.57  0.86 3.71 0.98 2.47  0.78 0.478 0.001
FEF75, l/s 1.70  0.90 1.63 0.58 1.02  0.39 0.866 0.001
PEF, l/s 8.15  1.48 8.15 1.44 6.45  1.65 0.968 0.001
Terbutaline
FEV1, l 3.65  0.64 3.82 0.68 3.43  0.63 0.001 0.001
FVC, l 4.74  0.94 4.73 0.95 4.62  0.95 0.796 0.001
FEF25–75, l/s 3.26  0.93 3.37 0.97 3.07  0.86 0.001 0.001
FEF25, l/s 6.15  1.32 6.78 1.41 5.57  1.32 0.001 0.001
FEF50, l/s 3.77  1.06 4.22 1.33 3.45  0.84 0.001 0.001
FEF75, l/s 1.62  0.61 2.16 1.43 1.47  0.50 0.001 0.001
PEF, l/s 7.95  1.41 8.27 1.50 7.38  1.31 0.001 0.001
Pre-Rx, pretreatment with either 0.5 mg terbutaline or placebo; Post-Rx, posttreatment; Post-EVH, min value, lowest value recorded after 8 min of eucapnic
voluntary hyperpnoea of dry air; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEF25–75, mean forced expiratory flow between 25 and 75%
of FVC; FEFX, forced expiratory flow at X% of FVC; PEF, peak expiratory flow.
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80 8% MVV during the terbutaline visit and 78 7% MVV
during the placebo visit (P  0.022).
Airway response to EVH. Terbutaline significantly inhibited
the airway response to EVH. The maximum fall in FEV1 was
reduced from 17  8% in the placebo condition to 8  5% in
the terbutaline condition (P 0.001, Table 1). FEV1-AUC0–60
was significantly reduced following terbutaline administration:
from 425  283 to 163  146% min (P  0.001, Fig. 1). The
bronchoprotection offered by terbutaline for the maximum
percent fall in FEV1 and FEV1 AUC0 – 60 was 54  28%
(range 0 –94%, Table 1) and 60  30% (range 0 –100%),
respectively. Terbutaline provided complete protection (i.e.,
post-EVH maximum %fall in FEV1 10%) to 22 of the 27
participants (81%).
EVH caused a significant decrease in FVC and in all expi-
ratory flow values in both conditions (P 0.001, Table 2). The
decrease in FVC post-EVH was significantly attenuated with
the administration of terbutaline (from 0.28  0.19 to 0.12 
0.11 l, P  0.001).
Urinary CC16. Three participants were excluded from the
urinary CC16 statistical analysis, since their CC16 concentra-
tions were below the detection point. In addition, one partici-
pant was excluded on the grounds of being an outlier. His
CC16 measurements were highly variable at baseline (2,457
and 1,055 pg/mol creatinine in the placebo and terbutaline
condition, respectively), and he was the only participant to
display a reduction in urinary CC16 excretion postchallenge in
both the placebo and terbutaline condition (1,582 and 261
pg/mol creatinine, respectively). The total number of data
analyzed for CC16 was therefore 23.
Baseline urinary CC16 was not significantly different be-
tween conditions: 266  329 in the placebo condition vs.
267  292 pg/mol creatinine in the terbutaline condition
(P  0.695). EVH caused a significant increase in urinary
excretion of CC16 in both conditions (P 0.001), but the peak
urinary release of CC16 postchallenge was significantly atten-
uated by terbutaline: from 682  788 to 582  741 pg/mol
creatinine (P  0.032). The magnitude of the change in urinary
CC16 (pre- to maximum postchallenge CC16) was also signifi-
cantly reduced after premedication with terbutaline (from 416 
495 to 315  523 pg/mol creatinine, P  0.016; Fig. 2).
Repeated-measures ANOVA revealed significant time (P 
0.001) and interaction (P  0.002) effects, which indicate that
terbutaline altered the kinetics of urinary CC16 excretion. Post
hoc analysis revealed that urinary CC16 increased significantly
from baseline to 30 and 60 min post-EVH in both conditions
(P  0.01). However, in the placebo condition, urinary CC16
continued to increase between 30 and 60 min of recovery (P 
0.033), whereas it started to plateau at 30 min of recovery in
the terbutaline condition. As a result, urinary concentrations of
CC16 were significantly lower in the terbutaline condition at
60 min recovery compared with placebo (P  0.007, Fig. 3).
Fig. 1. Mean  SE percentage changes from baseline (Pre-Rx) in forced
expiratory volume in 1 s (FEV1) after inhalation (Post-Rx) of 0.5 mg terbuta-
line () or placebo (Œ), and up to 60 min after eucapnic voluntary hyperpnoea
(EVH) of dry air in athletes with exercise-induced bronchoconstriction. Post-
EVH the area under the FEV1 time curve (measured from post-Rx) was
significantly reduced following administration of terbutaline (P  0.001).
Fig. 2. Maximum change in urinary excretion of CC16 following EVH of dry
air after pretreatment with placebo or 0.5 mg of terbutaline in athletes with
exercise-induced bronchoconstriction. Individual values with means (95%
confidence intervals). *P  0.05.
Fig. 3. Mean SE urinary CC16 concentrations at baseline and 30 and 60 min
post-EVH of dry air following pretreatment with 0.5 mg terbutaline () or
placebo (Œ) in athletes with exercise-induced bronchoconstriction. *P  0.05,
**P  0.01, and ***P  0.001.
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DISCUSSION
The aim of this study was to test the efficacy of inhaled
terbutaline at reducing hyperpnoea-induced airway epithelial
injury and bronchoconstriction in athletes. We showed that a
single therapeutic dose of terbutaline of 0.5 mg was able to
blunt the rise in urinary CC16 concentration following hyper-
pnoea of dry air. Moreover, we confirmed that terbutaline
provided a significant degree of bronchoprotection to the ma-
jority (81%) of the athletes. These results demonstrate the
potential for inhaled 2-agonists to attenuate, not only bron-
choconstriction, but also acute airway epithelial perturbation in
athletes with EIB.
This study supports our previous findings that hyperpnoea of
dry air causes perturbation to the airway epithelium in athletes
(6). It is also consistent with work conducted by our group (5)
and others (9, 10, 37) that showed that exercise hyperpnoea is
associated with an increase in serum and urinary concentration
of CC16 in athletes. The ability of parenteral 2-agonists to
reduce dry air-induced epithelial injury was previously dem-
onstrated in animals (33, 40). We have now extended these
findings by demonstrating that terbutaline can attenuate airway
epithelial perturbation when administered by inhalation in the
human lungs.
Airway epithelial perturbation in this study was assessed
through changes in urinary CC16 concentration. CC16 is a
protein secreted from the club cells located primarily in the
distal airways (38). Acute increases in the concentration of
CC16 in extrapulmonary fluids have previously been proposed
to reflect a transient loss of the lung epithelial barrier integrity
(20). An increase in urinary CC16 may also represent an
increase in CC16 production/secretion by club cells in an
attempt to modulate local inflammatory reactions (22). We
have previously shown that hyperpnoea of dry air is associated
with mast cell activation and inflammatory mediator release in
athletes (26). Therefore, the rise in urinary CC16 following
EVH in the current study may be the result of a combination of
increased leakage of CC16 across the airway epithelium and
increased production and/or secretion of the protein at the club
cell level.
The use of a noninvasive marker (with multiple sampling
time points) enabled us to test, for the first time, the efficacy of
a pharmacological agent at attenuating hyperpnoea-induced
airway perturbation in athletes. We showed that the rise in
urinary CC16 concentration following a short period of hyper-
pnoea of dry air was significantly blunted with premedication
with terbutaline. In vitro, terbutaline has been shown to in-
crease the flow of Cl toward the airway lumen (14), an action
likely to be mediated through binding of the drug with 2-
receptors on epithelial cells and subsequent release of cAMP
(39). Our research team previously demonstrated that reduction
of the dehydration stress to the airways through inhalation of
warm humid air limits epithelial cell perturbation after exercise
(5). Similarly, in the current study, we propose that the reduc-
tion in urinary CC16 excretion post-EVH was the result of
reduced dehydration of the airway epithelium mediated
through terbutaline-enhanced water secretion.
An alternative interpretation of the results is that terbutaline
did not affect the severity of epithelial perturbation per se but
rather enhanced the speed of epithelial cell repair. Perkins et al.
(34) showed in vitro that salbutamol stimulated both wound
repair and spreading and proliferation of human lung epithelial
cells. The potential of 2-agonists to stimulate epithelial cell
repair may explain why, in our study, urinary CC16 continued
to increase between 30 and 60 min of recovery in the placebo
condition, whereas it started to plateau in the terbutaline
condition. We propose that terbutaline was able to stimulate
the repair of the epithelial cells before the later time point (at
60 min), and therefore reduced leakage of CC16 across the
airway epithelial barrier.
A third contributing factor to our results could be the effect
of terbutaline on the bronchial vascular system. In a murine
model, terbutaline given in the instillate (intratracheally) re-
duced microvascular permeability during high-volume ventila-
tion (15). 2-agonists are thought to mediate vascular perme-
ability, either directly [by relaxing the endothelial contractile
proteins and thereby reducing gaps between endothelial cells
(41)] or indirectly [by inhibiting vasoactive mediator release
from the lung mast cells (13)]. We therefore cannot exclude
that terbutaline, by reducing vascular leakage, limited the
passage of CC16 in the bloodstream post-EVH.
Terbutaline in the present study was delivered through a dry
powder inhaler (Turbuhaler). When delivered via Turbuhaler,
terbutaline is known to reach all levels of the tracheobronchial
tree, including the small airways (30). In our study, we noticed
a significant increase in all forced expiratory flow parameters
(including FEF50 and FEF75) postadministration of terbutaline.
This is relevant in that the recruitment of the smaller airways
in the conditioning of inspired air has been highlighted as the
main mechanism for exercise-induced airway epithelial injury
(3). Terbutaline has the potential to enhance osmotic-driven
water flux to the airway lumen (14). Enhancement of water
secretion to the larger airways may have therefore reduced the
necessity for the smaller airways to be recruited in the condi-
tioning process and may have protected those smaller airways
against epithelial injury. The dispersion of terbutaline within
the airways is known to be dependent on the inspiratory flow
achieved with the Turbuhaler (31). Because inspiratory flow was
not controlled in our study, interindividual differences in disper-
sion of the medication may account for the variation in the
effectiveness of the terbutaline in attenuating the rise in CC16
post-EVH.
Although there was little difference in ventilation rates
achieved by the athletes between the terbutaline and the pla-
cebo conditions, bronchoconstriction was more severe after
placebo inhalation. Therefore, in our control condition, signif-
icant compressive stress may have occurred within the airways
(32), which may have further compromised the integrity of the
airway epithelial barrier. However, we did not find any signif-
icant correlation between the changes in urinary excretion of
CC16 and the fall in FEV1 post-EVH under our two experi-
mental conditions (data not shown). Similarly, in some of our
previous work (5, 6), there was no difference in magnitude of
urinary CC16 increase following exercise or EVH challenge
tests in individuals with and without EIB. This therefore
suggests that mild-to-moderate bronchoconstriction per se is
unlikely to affect the extent of perturbation to the airway
epithelium.
This paper is relevant to endurance athletes who are thought
to repeatedly damage their airways through dehydration stress
(3). Endurance (aerobic) athletes have an increased prevalence
of EIB compared with their counterparts who perform anaer-
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obic exercise and with the general population (11). Repeated
airway epithelial injury-repair has been highlighted as a key
factor contributing to the increased prevalence of airway hy-
perresponsiveness in elite endurance athletes (3). Strategies
aiming at preventing hyperpnoea-induced epithelial perturba-
tion may therefore be beneficial in the prevention of EIB (25).
Here, we showed that terbutaline acutely reduces airway epi-
thelial perturbation. Chronic use of inhaled 2-agonist may,
however, cause tachyphylaxis and failure to respond to emer-
gency bronchodilator treatment (19). Therefore, alternative
treatments that act via similar pathways to 2-agonists should
be explored to devise appropriate long-term prevention strate-
gies for airway injury in athletes.
In conclusion, this study demonstrates for the first time that
premedication with a single, inhaled dose of terbutaline re-
duces hyperpnoea-induced airway epithelial perturbation in
athletes. The evidence presented also provides further support
to the use of terbutaline for prevention of EIB in athletes. We
propose that terbutaline reduces epithelial perturbation mainly
by enhancing water movement toward the airway lumen and by
stimulating repair of the damaged airway epithelial cells.
Because of the potential side effects of chronic use of inhaled
2-agonists, we recommend that further research into the
prevention of airway injury in athletes is conducted, targeting
drugs that either enhance ion transport or stimulate epithelial
cell repair.
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